| Elevation of serum level of vascular endothelial growth factor as a new predictor of recurrence and disease progression in patients with superficial urothelial cancer. | |
| | |
MedLine Citation:
|
PMID: 9933044 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVES: To determine whether the serum vascular endothelial growth factor (VEGF) level in patients with urothelial cancer could be used as a predictor of recurrence and disease progression. METHODS: Serum levels of VEGF in 51 healthy controls and 135 patients with urothelial cancer (81 superficial and 54 invasive cancers) were measured using a sandwich enzyme immunoassay, and the results were analyzed with respect to several clinicopathologic factors. RESULTS: Significant differences in the serum VEGF level were observed between healthy controls and patients with superficial urothelial cancer (34+/-12 pg/mL versus 49+/-27 pg/mL, P<0.001) and between healthy controls and patients with invasive cancer (34+/-12 pg/mL versus 51+/-35 pg/mL, P<0.001), whereas there was no significant difference in the serum VEGF level between superficial and invasive cancers (49+/-27 pg/mL versus 51+/-35 pg/mL, P = 0.31). Among patients with superficial cancer, the disease-free survival rate of patients with elevated serum levels of VEGF was significantly lower than that of patients with normal levels (P<0.05). The progression-free survival rate of superficial cancer patients with elevated serum levels of VEGF was also significantly lower than that of patients with normal levels (P<0.01). In addition, Cox's multivariate analysis revealed that the elevation of serum VEGF level was strongly associated with disease-free survival and progression-free survival in patients with superficial cancer (P<0.05). CONCLUSIONS: The results of this study suggest that the elevation of serum VEGF level could be used as a new independent predictor of recurrence and disease progression in patients with superficial urothelial cancer. |
| | |
Authors:
|
H Miyake; I Hara; K Yamanaka; K Gohji; S Arakawa; S Kamidono |
Related Documents
:
|
871124 - Pharmacokinetics in drug therapy ii: applications of clinical pharmacokinetics in the a... 8582434 - Differential effect of cancer on the serum protein binding to mianserin and imipramine. 2646084 - The application of leukocyte adherence inhibition assay to patients with colorectal can... 4034144 - Determination of tissue polypeptide antigen (tpa) levels in different cancer types and ... 21263424 - Diaphragm perforation after radio-frequency ablation for metastatic lung cancer. 12676454 - Differentiating between local cytotoxicity, mitogenesis, and genotoxicity in carcinogen... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Urology Volume: 53 ISSN: 0090-4295 ISO Abbreviation: Urology Publication Date: 1999 Feb |
Date Detail:
|
Created Date: 1999-03-04 Completed Date: 1999-03-04 Revised Date: 2004-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 0366151 Medline TA: Urology Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 302-7 Citation Subset: IM |
Affiliation:
|
Department of Urology, Kobe University School of Medicine, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Aged, 80 and over Carcinoma, Transitional Cell / blood*, diagnosis* Disease Progression Endothelial Growth Factors / blood* Female Humans Lymphokines / blood* Male Middle Aged Neoplasm Recurrence, Local / blood*, diagnosis* Predictive Value of Tests Proportional Hazards Models Urologic Neoplasms / blood*, diagnosis* Vascular Endothelial Growth Factor A Vascular Endothelial Growth Factors |
| Chemical | |
Reg. No./Substance:
|
0/Endothelial Growth Factors; 0/Lymphokines; 0/Vascular Endothelial Growth Factor A; 0/Vascular Endothelial Growth Factors |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Orthotopic neobladder in management of tubercular thimble bladders: initial experience and long-term...
Next Document: Conservative therapy for stage T1b, grade 3 transitional cell carcinoma of the bladder.